Order Article Reprints

Dimitrakopoulos F-I, Nikolakopoulos A, Kottorou A, Kalofonou F, Liolis E, Frantzi T, Pyrousis I, Koutras A, Makatsoris T, Kalofonos H. PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. Cancers. 2020; 12(5):1257. https://doi.org/10.3390/cancers12051257

Dimitrakopoulos, Foteinos-Ioannis, Achilleas Nikolakopoulos, Anastasia Kottorou, Fotini Kalofonou, Elias Liolis, Theodora Frantzi, Ioannis Pyrousis, Angelos Koutras, Thomas Makatsoris, and Haralabos Kalofonos. 2020. "PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors" Cancers 12, no. 5: 1257. https://doi.org/10.3390/cancers12051257

Dimitrakopoulos, F.-I., Nikolakopoulos, A., Kottorou, A., Kalofonou, F., Liolis, E., Frantzi, T., Pyrousis, I., Koutras, A., Makatsoris, T., & Kalofonos, H. (2020). PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. Cancers, 12(5), 1257. https://doi.org/10.3390/cancers12051257